Brief: IRLAB Nominates IRL1117 As Drug Candidate To Develop Treatment For Parkinson's

IRLAB Therapeutics AB

12/01/2023 06:09

Jan 12 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * NOMINATES IRL1117 AS DRUG CANDIDATE FROM P003 PROJECT TO
DEVELOP
A NOVEL TREATMENT FOR PARKINSON'S DISEASE
    * INITIATION OF DEVELOPMENT TOWARDS CLINICAL STUDIES HAS
COMMENCED
AND IRL1117 IS EXPECTED TO START PHASE I STUDIES IN 2024

Source text for Eikon:  ID:nMFN110Tpy 
Further company coverage:  IRLABa.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))